同源康

ABOUT

TYK Medicines Focus on new drug research and development
Together, we search for the cure.

Discover More

NEWS

The Results of Asandeutertinib Tablets (TY-9591) will be Presented at the WCLC 2024

TYK Medicines Announced First Patient Dosed in Phase 1 clinical trial of its CDK2/4/6 inhibitor TYK-00540

TY-2136b granted Orphan Drug Designation in the US for Non-Small Cell Lung Cancer

RESEARCH

An innovative biotechnology company focusing on the research and development of innovative drugs